Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation

Lung Cancer 2023 June [Link] Akio Tada, Toshiyuki Minami, Hidemi Kitai, Yoko Higashiguchi, Mayuko Tokuda, Tomoki Higashiyama, Yoshiki Negi, Daisuke Horio, Yasuhiro Nakajima, Taiichiro Otsuki, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Kazuhiro Kitajima, Masaki Ohmuraya, Kozo Kuribayashi, Takashi Kijima Abstract Malignant pleural mesothelioma (MPM) is an asbestos-related fatal malignant neoplasm. Although there has been no…

Read More

Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study

BMC Cancer 2023 May 5 [Link] Yufei Liang, Chunying Li, Yingying Liu, Liang Tian, Dongliang Yang Abstract Background: Diagnosis and treatment of diffuse malignant peritoneal mesothelioma (DMPM) are still challenging. The aim of the present study was to explore the correlation between CD74, CD10, Ki-67 and clinicopathological parameters, and identify independent prognostic factors of DMPM.…

Read More

High Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma

Biomed Research International 2023 April 24 [Link] Guan-Ying Ma, Shuai Shi, Yin-Zhou Sang, Ping Wang, Zhi-Gang Zhang Abstract Background: To investigate the value of SMO and GLI1 genes in the hedgehog pathway in malignant mesothelioma specimens. Further study on the expression and prognosis of SMO and GLI1 in malignant mesothelioma tissues and the relationship between…

Read More

Comprehensive epithelial biomarker analysis of malignant mesothelioma: EpCAM positivity is a potential diagnostic pitfall

Cancer Cytopathology 2023 April 17 [Link] Yili Zhu, Simone Moore, Aihui Wang, Elizabeth George, Grace M Allard, Diane M Libert, Alarice C Lowe Abstract Background: Epithelial cell adhesion molecule (EpCAM) is frequently used to distinguish carcinoma from background mesothelial cells during cytologic examination of body cavity fluids. Previously, the authors identified one malignant mesothelioma case…

Read More

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy

International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…

Read More

TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy

Lung Cancer 2023 April [Link] Luca Hegedüs, Özlem Okumus, Fabian Mairinger, Till Ploenes, Sebastian Reuter, Martin Schuler, Anja Welt, Silvia Vega-Rubin-de-Celis, Dirk Theegarten, Agnes Bankfalvi, Clemens Aigner, Balazs Hegedüs Abstract Objectives: Malignant pleural mesothelioma (MPM) is an aggressive cancer which at large is not amenable to curative surgery. Despite the recent approval of immune checkpoint…

Read More

A novel prognostic nomogram for predicting survival in diffuse pleural mesothelioma

Pathology 2023 February 4 [Link] Yagiz Aksoy, Angela Chou, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa S Ahadi, Anthony J Gill, Talia L Fuchs Abstract Recent advances in the management of diffuse pleural mesothelioma (DPM) have increased interest in prognostication and risk stratification on the basis that maximum benefit of combination immunotherapy appears to be…

Read More

Neurofibromatosis Type 2-Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif Dual Immunohistochemistry Is a Reliable Marker for the Detection of Neurofibromatosis Type 2 Alterations in Diffuse Pleural Mesothelioma

Modern Pathology 2023 March [Link] Yan Li, Soo-Ryum Yang, Ying-Bei Chen, Prasad S Adusumilli, Ann Bialik, Francis M Bodd, Marc Ladanyi, Jessica Lopardo, Michael D Offin, Valerie W Rusch, William D Travis, Marjorie G Zauderer, Jason C Chang, Jennifer L Sauter Abstract Neurofibromatosis type 2 (NF2) loss occurs in approximately 30% to 50% of diffuse…

Read More